Balyasny Asset Management
CVS icon

Balyasny Asset Management’s CVS Health CVS Stock Holding History

Balyasny Asset Management’s Portfolio CVS Stock Details CVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85.5M Buy
1,191,023
+252,966
+27% +$19.5M 0.11% 193
2025
Q4 		$74.4M Buy
938,057
+527,393
+128% +$41.6M 0.09% 234
2025
Q3 		$31M Sell
410,664
-1,012,110
-71% -$69.4M 0.04% 529
2025
Q2 		$98.1M Buy
1,422,774
+262,354
+23% +$17.2M 0.15% 157
2025
Q1 		$78.6M Sell
1,160,420
-665,189
-36% -$39.8M 0.13% 182
2024
Q4 		$82M Buy
1,825,609
+959,335
+111% +$53.8M 0.12% 188
2024
Q3 		$54.5M Buy
866,274
+79,125
+10% +$4.62M 0.09% 279
2024
Q2 		$46.5M Sell
787,149
-41,989
-5% -$2.63M 0.08% 313
2024
Q1 		$66.1M Buy
829,138
+815,334
+5,907% +$62.3M 0.12% 221
2023
Q4 		$1.09M Sell
13,804
-396,531
-97% -$28.2M ﹤0.01% 1650
2023
Q3 		$28.6M Buy
410,335
+338,160
+469% +$24M 0.06% 450
2023
Q2 		$4.99M Sell
72,175
-567,631
-89% -$40.4M 0.01% 1063
2023
Q1 		$47.5M Buy
639,806
+604,087
+1,691% +$50.7M 0.12% 228
2022
Q4 		$3.33M Sell
35,719
-3,178
-8% -$307K 0.01% 1198
2022
Q3 		$3.71M Sell
38,897
-10,290
-21% -$1.02M 0.01% 1171
2022
Q2 		$4.56M Buy
49,187
+34,387
+232% +$3.36M 0.01% 983
2022
Q1 		$1.5M Sell
14,800
-458,449
-97% -$48.2M ﹤0.01% 1480
2021
Q4 		$48.8M Buy
473,249
+309,079
+188% +$28.6M 0.17% 137
2021
Q3 		$13.9M Sell
164,170
-25,479
-13% -$2.13M 0.06% 451
2021
Q2 		$15.8M Buy
189,649
+146,863
+343% +$12M 0.07% 362
2021
Q1 		$3.22M Buy
+42,786
New +$3.12M 0.02% 858
2020
Q2 		– Sell
-507,297
Closed -$30.1M – 1181
2020
Q1 		$30.1M Buy
507,297
+179,133
+55% +$12M 0.36% 62
2019
Q4 		$24.4M Sell
328,164
-103,562
-24% -$7.27M 0.14% 215
2019
Q3 		$27.2M Buy
431,726
+426,835
+8,727% +$25.3M 0.19% 163
2019
Q2 		$267K Sell
4,891
-239,979
-98% -$12.9M ﹤0.01% 1354
2019
Q1 		$13.2M Sell
244,870
-669,370
-73% -$41.3M 0.09% 323
2018
Q4 		$59.9M Buy
914,240
+817,338
+843% +$61M 0.43% 40
2018
Q3 		$7.63M Buy
+96,902
New +$6.93M 0.03% 573
2018
Q2 		– Sell
-33,609
Closed -$2.09M – 1839
2018
Q1 		$2.09M Sell
33,609
-308,245
-90% -$22.1M 0.01% 980
2017
Q4 		$24.8M Buy
341,854
+177,315
+108% +$12.9M 0.08% 338
2017
Q3 		$13.4M Buy
+164,539
New +$13M 0.05% 417
2017
Q2 		– Sell
-41,155
Closed -$3.23M – 1510
2017
Q1 		$3.23M Sell
41,155
-150,345
-79% -$12M 0.02% 801
2016
Q4 		$15.1M Sell
191,500
-8,349
-4% -$676K 0.08% 352
2016
Q3 		$17.8M Sell
199,849
-264,034
-57% -$24.9M 0.1% 267
2016
Q2 		$44.4M Buy
463,883
+391,026
+537% +$39M 0.29% 87
2016
Q1 		$7.56M Sell
72,857
-52,478
-42% -$5.1M 0.04% 464
2015
Q4 		$12.3M Buy
+125,335
New +$12.3M 0.09% 319
2015
Q2 		– Sell
-128,630
Closed -$13.3M – 1181
2015
Q1 		$13.3M Buy
+128,630
New +$13M 0.11% 279
2014
Q1 		– Sell
-193,010
Closed -$13.8M – 572
2013
Q4 		$13.8M Buy
+193,010
New +$12.4M 0.18% 150

Other funds holding CVS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Balyasny Asset Management's CVS Position: Q1 2026 in Review

Balyasny Asset Management increased its CVS Health (CVS) stake by 27% in Q1 2026, buying an estimated $19.5M and bringing the position to 1,191,023 shares worth $85.5M. The position accounts for 0.11% of the portfolio, ranked #193.

Balyasny Asset Management first reported a position in CVS in Q4 2013 and has held it in 39 quarters since. The position peaked at $98.1M in Q2 2025. 1,866 funds tracked by Wall St. Rank hold CVS as of Q1 2026.

  • Balyasny Asset Management held 1,191,023 shares of CVS Health worth $85.5M as of Q1 2026.
  • Balyasny Asset Management bought 252,966 CVS Health shares in Q1 2026, an estimated $19.5M.
  • CVS Health made up 0.11% of Balyasny Asset Management's portfolio in Q1 2026, its #193 holding.
  • Balyasny Asset Management first reported a position in CVS Health in Q4 2013 and has held it in 39 quarters since.
  • Balyasny Asset Management's CVS Health position peaked at $98.1M in Q2 2025.
  • 1,866 funds tracked by Wall St. Rank held CVS Health as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.